MARKET WIREYahoo Finance • 23h ago
Dr. Reddy's Laboratories: 3 Key Takeaways for Long-Term InvestorsYahoo Finance report covering Dr. Reddy's Laboratories Ltd (RDY) market action, institutional positioning, and fundamental catalysts.
Why RDY Stock slipped -0.28% Today — RQD Quant Desk Flash
$14.13 -0.28% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $14.10
Dr. Reddy's Laboratories Ltd (RDY) carries a Roarable Rating of C (Hold) with 64/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.
ROARABLE C • HOLD / WATCH
Cap $11.83B
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on RDY Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is RDY stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Dr. Reddy's Laboratories Ltd (NYSE: RDY) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 64/100 at a spot price of $14.13 (-0.28% 1D, market cap $11.83B). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 13/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 12/20, and Executive Insider Alignment 12/20. Across 1015 tracked Health Care issuers, RDY ranks #126 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does RDY compare to ELAN and BMRN in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RDY carries a Roarable C (64/100 RQD), trailing P/E of 32.8x, gross margin of —, and ROIC of 9.9%. By comparison, ELAN (Elanco Animal Health Incorporated) holds a D grade (45/100 RQD, P/E N/A, ROIC -2.5%, cap $11.52B) and BMRN (BioMarin Pharmaceutical Inc.) posts a B grade (74/100 RQD, P/E 31.9x, ROIC 6.0%, cap $11.33B). Among the 5-stock peer group, BMRN leads on earnings multiple (31.9x) while RDY leads on capital efficiency (9.9% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for RDY?
▼
For Dr. Reddy's Laboratories Ltd (RDY), key quantitative strengths include Clean SEC annual filing review with no major hidden accounting time-bombs and sector rank #126 in Health Care, while primary risk factors center on Broader market pullbacks can still drag down strong stocks in the short run and implied 5-year growth hurdle of 25.3%/yr. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $14.10 (-0.24%)🧬 Cannibal Buyback (-1.24% YoY Shares)⚙️ Cash Engine: 11/20 (D+) • 6.5% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 64/100 (C) historically posted market-perform odds over rolling 90-day windows (+1.1% avg 90D alpha vs SPY • 55.2% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →RQD QUANT TACHOMETERHOLD / WATCH • C
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw C- · Rk B-
Each axis scored 0–20
12M PRICE TARGET CONE+2.7% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for RDY)Realized 20D OHLCV Swing Band: ±3.6%
Deterministic 5-Pillar Attribution (64/100 Composite)
🔍 WHY RDY SCORES 64/100 (C) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (25% of score)
Altman Z-Score 3.74 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 8/9
▲ #2 Bullish Driver: Whale & Options Positioning+13/20 pts (20% of score)
20D Institutional Volume Accumulation (±3.6% realized swing band)
▼ #1 Drag / Risk Factor: Cash Engine Quality11/20 pts (-9 pt drag)
Capital intensity & 13.9% operating margin leave 9 pts on the table
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C$12.75+3.5% Next Q
56
Q2 (-2Q)Grade C$13.19+7.3% Next Q
59
Q3 (-1Q)Grade C$14.15-0.1% Next Q
61
CurrentGrade C$14.13+1.1% Hist 90D α
64
Trajectory: C (56) → C (64)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER
⚔️ Adversarial Opposing Case: Why the RDY Bull Thesis Could Fail
Even with a 64/100 (C) score, RDY faces multiple-compression risk if 32.8x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
⚠️ Forensic Kill-Switch #1
Broader market pullbacks can still drag down strong stocks in the short run.
⚠️ Forensic Kill-Switch #2
Dilution & Margin Drag: Cannibal Buyback (-1.24% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.
⚠️ Forensic Kill-Switch #3
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($12.65) or 200D SMA ($13.23) invalidates the momentum regime and cuts Target Base ($14.51) toward Bear Floor ($11.32).
🎲 LIVE PREDICTION MARKET ODDS TIED TO $RDY• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “RDY Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why RDY Stock slipped -0.28% Today — RQD Quant Desk Flash
Dr. Reddy's Laboratories Ltd (RDY) slipped -0.28% to $14.13, trading at 64% of its 52-week range ($11.36 – $15.67). Solid steady margins (10% return on capital), mixed timing at 33x P/E—hold if owned, no rush to chase.
- ▸Technical Tape: Trading at 64% of its 52-week range ($11.36 – $15.67) with RSI-14 at 76.2 (OVERBOUGHT (>70)).
- ▸Volatility Profile: Historical 20-day realized swing band of ±3.6% around $14.13 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable C (Hold) backed by 52% gross margin and $261.4M annual free cash flow.
Live RDY Headlines & Catalysts
MARKET WIREMoomoo • 1d ago
Dr. Reddy's Laboratories(RDY) Stock Options Chain | Quotes & NewsMoomoo report covering Dr. Reddy's Laboratories Ltd (RDY) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESeeking Alpha • 1d ago
Dr. Reddy's Laboratories Limited 2027 Q2 - Results - Earnings Call Presentation (NYSE:RDY) 2026-10-23Seeking Alpha report covering Dr. Reddy's Laboratories Ltd (RDY) market action, institutional positioning, and fundamental catalysts.
CATALYSTGuruFocus • 1d ago
Dr Reddy's Laboratories Ltd (RDY) Shares Surge 4.1% -- What GF SGuruFocus report covering Dr. Reddy's Laboratories Ltd (RDY) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingView • 1d ago
Dr. Reddy's Laboratories Q2 Earnings Call HighlightsTradingView report covering Dr. Reddy's Laboratories Ltd (RDY) market action, institutional positioning, and fundamental catalysts.
CATALYSTMarketBeat • 1d ago
Dr. Reddy's Laboratories (NYSE:RDY) Stock Jumps 4.8% After Strong EarningsMarketBeat report covering Dr. Reddy's Laboratories Ltd (RDY) market action, institutional positioning, and fundamental catalysts.
RISK WATCHQuiver Quantitative • 1d ago
Dr. Reddy's Laboratories (RDY) Stock Falls on Q2 2027 EarningsQuiver Quantitative report covering Dr. Reddy's Laboratories Ltd (RDY) market action, institutional positioning, and fundamental catalysts.
MARKET WIREFintel • 5d ago
Dr. Reddy's Laboratories Limited Announces USFDA Classifies FTO-SEZ Process Unit-02 Inspection as Voluntary Action IndicatedRISK WATCHYahoo • 7d ago
RDY Q2 Earnings & Revenues Miss Estimates as Lenalidomide Sales FallDr. Reddy's Q2 earnings and revenues miss estimates as lower lenalidomide sales weigh on results despite growth in India and emerging markets.
MARKET WIRESeekingAlpha • 10d ago
Dr. Reddy's Laboratories Limited (RDY) Q2 2027 Earnings Call TranscriptON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk
Scheduled RQD Strong Buys & Whale Accumulation Briefing (RDY Tape Review)
- ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
- ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
- ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
RDY // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +5.84%⚡ TESTING RESISTANCE
2026-11-03O $14.11H $14.17L $14.11C $14.13VOL 1.83M
RES: $14.27SUP: $11.65SMA50: $12.65SMA200: $13.23
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
RDY Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
25.3%/yr Implied 5Y Growth
vs. +6.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on RDY today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for RDY. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for RDY today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (RDY)
Health Care Rank #126 of 1015
⚔️ ELAN vs RDY Full Matrix →
1. Head-to-Head Health Care Peer Comparison (RDY vs. ELAN, BMRN, SMMT, SYRE)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, Dr. Reddy's Laboratories Ltd (RDY) ranks #126 by composite RQD confidence (64/100, grade C) and #92 by equity capitalization ($11.83B). Within this direct 5-issuer industry benchmark cohort, BMRN leads on earnings valuation at 31.9x trailing P/E, while RDY leads on capital efficiency and profitability with 9.9% ROIC and — gross margin. BMRN currently holds the highest overall quantitative score in the immediate peer group at 74/100 (B) compared with RDY at 64/100 (C).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| RDY
ACTIVE
Dr. Reddy's Laboratories Ltd | C | 64/100 | 32.8x | — | 9.9% | -0.28% | $11.83B | Benchmark Subject |
| ELAN Elanco Animal Health Incorporated | D | 45/100 | — | 55.0% | -2.5% | +4.51% | $11.52B | /elan-vs-rdy → |
| BMRN BioMarin Pharmaceutical Inc. | B | 74/100 | 31.9x | 77.7% | 6.0% | -1.83% | $11.33B | /bmrn-vs-rdy → |
| SMMT Summit Therapeutics Inc. | D- | 40/100 | — | — | -35.0% | -7.67% | $12.82B | /smmt-vs-rdy → |
| SYRE Spyre Therapeutics Inc. | D+ | 55/100 | — | — | -20.0% | -1.09% | $10.08B | /syre-vs-rdy → |
2. RDY Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics
TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOTDr. Reddy's Laboratories Ltd (RDY) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $11.83B, trailing P/E of 32.8x, forward P/E of 30.5x, and EV/EBITDA of 21.0x. Operating profitability registers a gross margin of —, operating margin of 13.9%, net profit margin of 10.9%, ROIC of 9.9%, and free cash flow yield of 2.21%, alongside an Altman Z-Score of 3.74 and Piotroski F-Score of 8/9.
3. RDY Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs RDY stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Dr. Reddy's Laboratories Ltd (NYSE: RDY) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 64/100 at a spot price of $14.13 (-0.28% 1D, market cap $11.83B). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 13/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 12/20, and Executive Insider Alignment 12/20. Across 1015 tracked Health Care issuers, RDY ranks #126 in composite RQD confidence.
How does RDY compare to ELAN and BMRN in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RDY carries a Roarable C (64/100 RQD), trailing P/E of 32.8x, gross margin of —, and ROIC of 9.9%. By comparison, ELAN (Elanco Animal Health Incorporated) holds a D grade (45/100 RQD, P/E N/A, ROIC -2.5%, cap $11.52B) and BMRN (BioMarin Pharmaceutical Inc.) posts a B grade (74/100 RQD, P/E 31.9x, ROIC 6.0%, cap $11.33B). Among the 5-stock peer group, BMRN leads on earnings multiple (31.9x) while RDY leads on capital efficiency (9.9% ROIC).
What are the biggest fundamental strengths and SEC risk factors for RDY?
For Dr. Reddy's Laboratories Ltd (RDY), key quantitative strengths include Clean SEC annual filing review with no major hidden accounting time-bombs and sector rank #126 in Health Care, while primary risk factors center on Broader market pullbacks can still drag down strong stocks in the short run and implied 5-year growth hurdle of 25.3%/yr. Institutional options positioning shows a 50% call / 50% put premium split.
Where is RDY trading relative to its 50-day, 200-day, and 52-week technical levels?
RDY last traded at $14.13 (-0.28% on volume of 1,932,026 shares), positioning the stock +11.70% above its 50-day simple moving average ($12.65) and +6.80% above its 200-day simple moving average ($13.23). Across its 52-week range of $11.36 to $15.67, RDY sits at the 64.3% percentile with a 14-day RSI of 76.2 (OVERBOUGHT (>70)) and an implied next-earnings move of ±3.6% ($13.62 to $14.64).
ROARABLE RATING BRIEF • RQD 64/100 (C)
✓ SEC XBRL & RQD VERIFIED
RDY — Dr. Reddy's Laboratories Ltd: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2026-11-03
1. Roarable Rating Brief: What This Means to a Prospective Investor
Dr. Reddy's Laboratories Ltd (RDY) earns a live Roarable RQD composite score of 64/100, corresponding to a C letter grade (Roarable Hold) at a spot price of $14.13 (-0.28% 1D, market capitalization $11.83B).
- Fundamental Cash Engine (11/20): Anchored by return on invested capital (ROIC) of 9.9%, gross margin of —, operating margin of 13.9%, and free cash flow yield of 2.21%.
- Whale 13F & Options Flow (13/20) + Insider Conviction (12/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (12/20) + Forensic Balance Sheet (16/20): Incorporates a 1.05x equity beta, Altman Z-Score of 3.74, Piotroski F-Score of 8/9, and Debt/Equity of 0.39x.
2. Business Model, Unit Margins & SEC Financial Trajectory
Dr. Reddy's Laboratories Ltd is a NYSE-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry,. Per the market data, the company reports an operating margin of 13.9% and a net margin of 10.9%.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (C • RQD 64/100): Clean SEC annual filing review with no major hidden accounting time-bombs. Free cash flow yield of 2.21% and institutional whale pillar of 13/20. With Fundamental Cash Engine at 11/20 and Institutional Whale Flow at 13/20, sustained execution supports upside toward the upper end of the $11.36 – $15.67 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Broader market pullbacks can still drag down strong stocks in the short run. Investors must weigh 32.8x trailing P/E and 21.0x EV/EBITDA against 13.9% operating margins and a 1.05x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
No upstream or downstream dependencies, sector correlations, or proprietary signals are recorded.
From a sector-analysis standpoint only: pharmaceutical preparation companies are commonly exposed to regulatory decisions, drug pricing, and generic competition, but none of these exposures are documented for RDY in the source data. Investors should treat these as open questions rather than established risks for this issuer.
- Key Question #1: Can RDY sustain or expand its 13.9% operating margin and 9.9% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
- Key Question #2: Will free cash flow conversion (2.21% FCF yield) strengthen balance-sheet liquidity (Altman Z-Score 3.74) toward the $15.67 52-week high?
- Key Question #3: How sensitive is RDY's 30.5x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.05x)?
RDY Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Dr. Reddy's Laboratories Ltd (RDY) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo Finance • 23h ago
Dr. Reddy's Laboratories: 3 Key Takeaways for Long-Term Investors Yahoo Finance report covering Dr. Reddy's Laboratories Ltd (RDY) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Moomoo • 1d ago
Dr. Reddy's Laboratories(RDY) Stock Options Chain | Quotes & News Moomoo report covering Dr. Reddy's Laboratories Ltd (RDY) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Seeking Alpha • 1d ago
Dr. Reddy's Laboratories Limited 2027 Q2 - Results - Earnings Call Presentation (NYSE:RDY) 2026-10-23 Seeking Alpha report covering Dr. Reddy's Laboratories Ltd (RDY) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST GuruFocus • 1d ago
Dr Reddy's Laboratories Ltd (RDY) Shares Surge 4.1% -- What GF S GuruFocus report covering Dr. Reddy's Laboratories Ltd (RDY) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 1d ago
Dr. Reddy's Laboratories Q2 Earnings Call Highlights TradingView report covering Dr. Reddy's Laboratories Ltd (RDY) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST MarketBeat • 1d ago
Dr. Reddy's Laboratories (NYSE:RDY) Stock Jumps 4.8% After Strong Earnings MarketBeat report covering Dr. Reddy's Laboratories Ltd (RDY) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH Quiver Quantitative • 1d ago
Dr. Reddy's Laboratories (RDY) Stock Falls on Q2 2027 Earnings Quiver Quantitative report covering Dr. Reddy's Laboratories Ltd (RDY) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
RDY Bull vs. Bear Conversation Board — What's Your Call at $14.13?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON RDY 🐻 33% BEARISH CONVICTION
DE DeepValue_CFA RQD DEBATE OPENER • Institutional Buy-Side 🐂 BULLISH
🎯 Target: $18.56 (+31.0%)
📌 Pinned Debate Per the Roarable RQD rating, the Forensic Balance Sheet pillar scores 16/20 with Altman Z 3.74, Piotroski F 8/9, and Debt/Equity 0.39,
Don't sleep on RDY's setup in Health Care. Per the Roarable RQD rating, the Forensic Balance Sheet pillar scores 16/20 with Altman Z 3.74, Piotroski F 8/9, and Debt/Equity 0.39, indicating financial strength.. Beta of 1.05 means it moves fast when momentum turns, and the 5-pillar RQD gauge (64/100) backs up the fundamental quality.
ArenaChamp_24 🐂 BULL
@DeepValue_CFA Agree on the RQD 64/100 quality, though with 1.05 beta I'm scaling in with half-size at $14.17 and keeping dry powder in case we test $13.18.
FA FadeTheHype RQD DEBATE OPENER • Contrarian Tape Reader 🐻 BEARISH
🎯 Target: $11.90 (-16.0%)
Spot @ $14.17 Per the market data, a P/E (TTM) of 32.8 and FCF yield of 2.21% indicate a demanding valuation relative to current cash generation.
Sitting on the sidelines or leaning short RDY above $14.17. Per the market data, a P/E (TTM) of 32.8 and FCF yield of 2.21% indicate a demanding valuation relative to current cash generation.. Until Fundamental Cash Engine (11/20) and FCF yield (2.21%) inflect higher, upside is capped near $15.67.